Loading
A phase 1 trial of CX-801 run by CytomX Therapeutics, now recruiting.
First In Human Study of CX-801 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT06462794 by CytomX Therapeutics, with 121 participants planned, started 2024-08-28. Conditions recorded: Solid Tumor, Adult. Interventions recorded: CX-801 and pembrolizumab.
Shares CytomX Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CytomX Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CytomX Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/